Testing how safe MDMA is for people with schizophrenia
Treatments studied
Part of Mental health clinical trials.
This early-phase study looks at whether MDMA is tolerable (safe enough) in people diagnosed with schizophrenia. Researchers will check safety while you stay stable on your usual care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 60 years old
- You can understand spoken English well enough to follow study instructions
- A clinician has diagnosed you with schizophrenia using a structured interview
- Your symptoms and treatment are stable for the past 6 months (no hospital stay and no medication changes)
- You have no recent substance/alcohol use disorder in the past 6 months
- You must not take certain medicines around testing (no benzodiazepines/sedatives in the prior 24 hours; no SSRIs/SNRIs)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a single medicine intended to help people with schizophrenia who cannot take standard antipsychotic medications due to side effects or poor response. It may help reduce schizophrenia symptoms, but whether you can join depends on your diagnosis, medication history, and health conditions.
This trial tests if MDMA-assisted therapy can help mental healthcare providers. It involves taking MDMA in a therapeutic setting while being recorded, and you must be trained in this type of therapy.
This Phase 1 study tests how MDMA behaves and is tolerated in people with moderate liver impairment compared with people whose livers work normally. It may help doctors understand dosing and safety for people with liver disease.
This Phase 2 study tests whether MDMA combined with structured therapy can reduce stress symptoms in people who have been exposed to major work-related stress in healthcare or emergency response. It’s designed to help participants during special “experimental” sessions plus regular therapy sessions without MDMA.
This trial tests whether high-dose MDMA, given during intensive inpatient therapy, can help people with PTSD that hasn't improved with other treatments. It takes place at a specialized trauma center and involves several therapy sessions with the drug.
This trial tests if a single dose of MDMA, given under supervision, can help people with borderline personality disorder (BPD). You will stay overnight after the session and be followed up for two weeks.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.